4
Changes in Ownership
Keros Therapeutics, Inc. Filed Acc 0001797917-26-000011
Director sold 575 shares at an average $10.83 ($6,230)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Prener Anne · Director
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-11-17 | Sale : show line 1 in the form 10b5-1 | −433 | $10.77 | $4,663 | 12,779 | D |
| 2026-11-17 | Sale : show line 2 in the form 10b5-1 | −142 | $11.03 | $1,566 | 12,637 | D |
| Open-market sales · 575 sh · avg $10.83 · $6,230 | ||||||
Loading xslF345X06/form4-11192026_041101.xml…